BR0012443A - Lipolìmero neutro e composições de lipossoma contendo o mesmo - Google Patents
Lipolìmero neutro e composições de lipossoma contendo o mesmoInfo
- Publication number
- BR0012443A BR0012443A BR0012443-5A BR0012443A BR0012443A BR 0012443 A BR0012443 A BR 0012443A BR 0012443 A BR0012443 A BR 0012443A BR 0012443 A BR0012443 A BR 0012443A
- Authority
- BR
- Brazil
- Prior art keywords
- neutral
- lipopolymers
- liposomes
- lipolymer
- compositions containing
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title abstract 5
- 230000007935 neutral effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- -1 aryl carbamate Chemical compound 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001733 carboxylic acid esters Chemical class 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Polyethers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Materials For Medical Uses (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Patente de Invenção: "LIPOLìMERO NEUTRO E COMPOSIçõES DE LIPOSSOMA CONTENDO O MESMO". Lipossomas contendo lipopolímeros neutros substituídos por PEG fornecem tempos de circulação similares os lipossomas que incorporam fosfolipídeos substituídos por PEG negativamente carregados convencionais. O uso dos lipopolímeros não carregados pode também apresentar vantagens em termos de interações com as superfícies celulares e vazamento reduzido de substâncias carregadas, particularmente drogas catiónicas, dos lipossomas. Os lipopolímeros são da fórmula (1) em que cada um de R^ 1^ e R^ 2^ é uma cadeia de alquila ou alquenila tendo entre cerca de 8 a cerca de 24 átomos de carbono; n é de cerca de 10 a cerca de 300, Z é selecionado do grupo que consiste em hidróxi, alcóxi, benzilóxi, éster carboxílico, éster suifónico, carbamato de alquila ou de arila, amino e alquilamino e a ligação L é selecionada do grupo que consiste em (i) -X-(C=O)-Y-CH~ 2~-, (ii) X-(C=O)- e (iii) -X-CH~ 2~-, em que X e Y são independentemente selecionados de oxigênio, NH, e uma ligação direta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14381099P | 1999-07-14 | 1999-07-14 | |
| PCT/US2000/018949 WO2001005873A1 (en) | 1999-07-14 | 2000-07-12 | Neutral lipopolymer and liposomal compositions containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0012443A true BR0012443A (pt) | 2002-04-02 |
Family
ID=22505748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0012443-5A BR0012443A (pt) | 1999-07-14 | 2000-07-12 | Lipolìmero neutro e composições de lipossoma contendo o mesmo |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6586001B1 (pt) |
| EP (1) | EP1198490B1 (pt) |
| JP (1) | JP2003505401A (pt) |
| KR (2) | KR20070086708A (pt) |
| CN (1) | CN1193059C (pt) |
| AT (1) | ATE317869T1 (pt) |
| AU (1) | AU769517B2 (pt) |
| BR (1) | BR0012443A (pt) |
| CA (1) | CA2379060A1 (pt) |
| CY (1) | CY1105466T1 (pt) |
| CZ (1) | CZ2002140A3 (pt) |
| DE (1) | DE60026030T2 (pt) |
| DK (1) | DK1198490T3 (pt) |
| ES (1) | ES2255501T3 (pt) |
| HK (1) | HK1048484B (pt) |
| HU (1) | HUP0202177A3 (pt) |
| IL (2) | IL147564A0 (pt) |
| MX (1) | MXPA02000402A (pt) |
| NO (1) | NO20020175L (pt) |
| PL (1) | PL352711A1 (pt) |
| PT (1) | PT1198490E (pt) |
| RU (1) | RU2250911C2 (pt) |
| WO (1) | WO2001005873A1 (pt) |
| ZA (1) | ZA200200303B (pt) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60117858T2 (de) * | 2000-12-07 | 2006-11-30 | Universiteit Utrecht Holding B.V. | Zusammensetzung zur behandlung von entzündlichen erkrankungen |
| WO2002087541A1 (en) * | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
| WO2003103594A2 (en) | 2002-06-07 | 2003-12-18 | Rutgers, The State University | Micelle assemblies |
| JP4722481B2 (ja) | 2002-06-28 | 2011-07-13 | プロティバ バイオセラピューティクス リミテッド | リポソーム製造方法および装置 |
| CN100379404C (zh) * | 2003-02-28 | 2008-04-09 | 阿尔扎公司 | 用于减少脂质体诱导的补体激活的脂质体组合物 |
| US20040213835A1 (en) * | 2003-02-28 | 2004-10-28 | Samuel Zalipsky | Method to reduce liposome-induced complement activation |
| WO2004087097A2 (en) * | 2003-03-31 | 2004-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
| ES2307009T3 (es) * | 2003-04-15 | 2008-11-16 | Opperbas Holding B.V. | Composicion farmaceutica que contiene proteinas y/o polipeptidos y particulas coloidales. |
| US7947261B2 (en) | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| KR101128320B1 (ko) * | 2003-05-23 | 2012-04-12 | 넥타르 테라퓨틱스 | 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체 |
| CA2527625A1 (en) * | 2003-05-30 | 2004-12-23 | Alza Corporation | Method of pulmonary administration of an agent |
| EP1648519B1 (en) * | 2003-07-16 | 2014-10-08 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
| CA2551022C (en) | 2003-09-15 | 2013-06-04 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| CA2542804A1 (en) * | 2003-10-24 | 2005-05-06 | Alza Corporation | Preparation of lipid particles |
| KR20060103957A (ko) * | 2004-01-15 | 2006-10-04 | 알자 코포레이션 | 치료제 전달용의 리포솜 조성물 |
| JP4796062B2 (ja) | 2004-06-07 | 2011-10-19 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質封入干渉ｒｎａ |
| TW200618820A (en) * | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
| CA2587470A1 (en) * | 2004-11-15 | 2006-05-18 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Combination therapy associating preferably a ceramide with a cytotoxic drug |
| TW200726485A (en) * | 2005-07-01 | 2007-07-16 | Alza Corp | Liposomal delivery vehicle for hydrophobic drugs |
| US8998881B2 (en) | 2005-08-10 | 2015-04-07 | Alza Corporation | Method for delivering drugs to tissue under microjet propulsion |
| IN2015DN00255A (pt) * | 2006-10-03 | 2015-06-12 | Alnylam Pharmaceuticals Inc | |
| CN101583380B (zh) * | 2006-11-30 | 2013-07-10 | 尼克塔治疗公司 | 用于制备聚合物轭合物的方法 |
| WO2008096690A1 (ja) * | 2007-02-05 | 2008-08-14 | Nippon Shinyaku Co., Ltd. | ポリエチレングリコール誘導体 |
| WO2008097623A2 (en) | 2007-02-07 | 2008-08-14 | Gradalis, Inc. | Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy |
| CA2711236A1 (en) * | 2008-01-02 | 2009-07-16 | Alnylam Pharmaceuticals, Inc. | Screening method for selected amino lipid-containing compositions |
| HUE034483T2 (en) | 2008-04-15 | 2018-02-28 | Protiva Biotherapeutics Inc | New lipid preparations for introducing a nucleic acid |
| KR100967833B1 (ko) | 2008-05-20 | 2010-07-05 | 아이디비켐(주) | 고순도의 폴리에틸렌글리콜 알데하이드 유도체의 제조방법 |
| US9173840B2 (en) | 2008-10-09 | 2015-11-03 | Northeastern University | Multifunctional self-assembling polymeric nanosystems |
| US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| EP2408916A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| MX2011009724A (es) | 2009-03-19 | 2011-10-14 | Merck Sharp & Dohme | Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen del factor de transcripcion basico de cierre de leucina 1 de homologia de btb y cnc 1, usando el listado de secuencias de acido nucleico corto de interferencia. |
| CN102439152A (zh) | 2009-03-27 | 2012-05-02 | 默沙东公司 | 使用短干扰核酸（siNA）的RNA干扰介导的细胞间粘附分子1（ICAM-1）基因表达的抑制 |
| US20120022143A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA) |
| JP2012521760A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| EP2411018A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| EP2411019A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| EP2449114B9 (en) | 2009-07-01 | 2017-04-19 | Protiva Biotherapeutics Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| JP5605760B2 (ja) * | 2010-01-18 | 2014-10-15 | セイコーエプソン株式会社 | 吐出用液体、生体試料の吐出方法、及び化合物 |
| WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
| RU2624045C2 (ru) | 2010-08-17 | 2017-06-30 | Сирна Терапьютикс,Инк | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| KR20130137160A (ko) | 2010-08-24 | 2013-12-16 | 머크 샤프 앤드 돔 코포레이션 | 내부의 비－핵산 스페이서를 함유하는 단일－가닥 ＲＮＡｉ 작용제 |
| EP2609106A4 (en) | 2010-08-26 | 2014-03-19 | Merck Sharp & Dohme | RNA INTERFERENCE-MEDIATED INHIBITION OF EXPRESSION OF PHD2 GENE (PROLYL HYDROXYLASE DOMAIN 2) USING SMALL INTERFERING NUCLEIC ACID (PANI) |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| AU2012207606B2 (en) * | 2011-01-11 | 2017-02-23 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| US8846850B2 (en) | 2011-02-22 | 2014-09-30 | Rutgers, The State University Of New Jersey | Amphiphilic macromolecules for nucleic acid delivery |
| US8785660B2 (en) * | 2011-03-29 | 2014-07-22 | Nof Corporation | Polyoxyalkylene-modified lipid and method for producing the same |
| JP6051758B2 (ja) | 2011-10-17 | 2016-12-27 | 日油株式会社 | ジアシルグリセロールと結合した分岐型ポリエチレングリコール、その製造方法およびポリエチレングリコール修飾リポソーム |
| EP2861558B1 (en) | 2012-06-15 | 2017-01-18 | Rutgers, The State University of New Jersey | Macromolecules for treating atherosclerosis |
| US10138203B2 (en) | 2014-06-16 | 2018-11-27 | Rutgers, The State University Of New Jersey | Antibacterial agents |
| US9630905B2 (en) | 2014-09-08 | 2017-04-25 | Rutgers, The State University Of New Jersey | Amphiphilic macromolecules and methods of use thereof |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| WO2017165836A1 (en) | 2016-03-24 | 2017-09-28 | Rutgers, The State University Of New Jersey | Antibacterial agents |
| WO2018027227A1 (en) | 2016-08-05 | 2018-02-08 | Rutgers, The State University Of New Jersey | Thermocleavable friction modifiers and methods thereof |
| MX2023006056A (es) | 2020-11-25 | 2023-06-06 | Akagera Medicines Inc | Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas. |
| GB202111757D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
| GB202111759D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles |
| GB202111758D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
| CA3234811A1 (en) | 2021-10-20 | 2023-04-27 | Steven Goldman | Rejuvenation treatment of age-related white matter loss |
| US12064479B2 (en) | 2022-05-25 | 2024-08-20 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2024163747A2 (en) | 2023-02-02 | 2024-08-08 | University Of Rochester | Competitive replacement of glial cells |
| WO2024220653A1 (en) | 2023-04-19 | 2024-10-24 | Gradalis, Inc. | Compositions and methods for modulating sialic acid production and treating hereditary inclusion body myopathy (hibm) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2694893A1 (fr) * | 1992-08-03 | 1994-02-25 | Oreal | Composition formée d'une dispersion aqueuse de vésicules de lipides amphiphiles non-ioniques stabilisées. |
| US5741518A (en) * | 1992-08-03 | 1998-04-21 | L'oreal | Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids |
| US5786387A (en) | 1994-03-23 | 1998-07-28 | Meiji Seika Kabushiki Kaisha | Lipid double-chain derivative containing polyoxyethylene |
| US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| TW520297B (en) * | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
| EP0957929B1 (en) * | 1996-10-25 | 2006-02-22 | Gilead Sciences, Inc. | Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
-
2000
- 2000-07-12 CN CNB008102988A patent/CN1193059C/zh not_active Expired - Fee Related
- 2000-07-12 WO PCT/US2000/018949 patent/WO2001005873A1/en active IP Right Grant
- 2000-07-12 CA CA002379060A patent/CA2379060A1/en not_active Abandoned
- 2000-07-12 BR BR0012443-5A patent/BR0012443A/pt not_active Application Discontinuation
- 2000-07-12 MX MXPA02000402A patent/MXPA02000402A/es active IP Right Grant
- 2000-07-12 RU RU2002100651/04A patent/RU2250911C2/ru not_active IP Right Cessation
- 2000-07-12 JP JP2001511524A patent/JP2003505401A/ja not_active Abandoned
- 2000-07-12 PL PL00352711A patent/PL352711A1/xx not_active Application Discontinuation
- 2000-07-12 AU AU59303/00A patent/AU769517B2/en not_active Ceased
- 2000-07-12 DE DE60026030T patent/DE60026030T2/de not_active Expired - Fee Related
- 2000-07-12 ES ES00945341T patent/ES2255501T3/es not_active Expired - Lifetime
- 2000-07-12 PT PT00945341T patent/PT1198490E/pt unknown
- 2000-07-12 KR KR1020077014651A patent/KR20070086708A/ko not_active Application Discontinuation
- 2000-07-12 KR KR1020027000531A patent/KR100758158B1/ko not_active IP Right Cessation
- 2000-07-12 DK DK00945341T patent/DK1198490T3/da active
- 2000-07-12 AT AT00945341T patent/ATE317869T1/de not_active IP Right Cessation
- 2000-07-12 IL IL14756400A patent/IL147564A0/xx active IP Right Grant
- 2000-07-12 EP EP00945341A patent/EP1198490B1/en not_active Expired - Lifetime
- 2000-07-12 CZ CZ2002140A patent/CZ2002140A3/cs unknown
- 2000-07-12 HU HU0202177A patent/HUP0202177A3/hu unknown
- 2000-07-13 US US09/615,552 patent/US6586001B1/en not_active Expired - Lifetime
-
2002
- 2002-01-10 IL IL147564A patent/IL147564A/en not_active IP Right Cessation
- 2002-01-14 NO NO20020175A patent/NO20020175L/no not_active Application Discontinuation
- 2002-01-14 ZA ZA200200303A patent/ZA200200303B/xx unknown
-
2003
- 2003-01-24 HK HK03100630.3A patent/HK1048484B/zh not_active IP Right Cessation
-
2006
- 2006-05-05 CY CY20061100593T patent/CY1105466T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60026030T2 (de) | 2006-08-10 |
| HUP0202177A3 (en) | 2004-05-28 |
| IL147564A (en) | 2007-03-08 |
| US6586001B1 (en) | 2003-07-01 |
| CN1360611A (zh) | 2002-07-24 |
| CN1193059C (zh) | 2005-03-16 |
| NO20020175D0 (no) | 2002-01-14 |
| PT1198490E (pt) | 2006-06-30 |
| AU769517B2 (en) | 2004-01-29 |
| ATE317869T1 (de) | 2006-03-15 |
| KR100758158B1 (ko) | 2007-09-12 |
| WO2001005873A1 (en) | 2001-01-25 |
| ES2255501T3 (es) | 2006-07-01 |
| DE60026030D1 (de) | 2006-04-20 |
| CY1105466T1 (el) | 2010-04-28 |
| HUP0202177A2 (hu) | 2002-12-28 |
| CA2379060A1 (en) | 2001-01-25 |
| PL352711A1 (en) | 2003-09-08 |
| HK1048484A1 (en) | 2003-04-04 |
| DK1198490T3 (da) | 2006-06-19 |
| HK1048484B (zh) | 2005-10-14 |
| IL147564A0 (en) | 2002-08-14 |
| NO20020175L (no) | 2002-01-14 |
| MXPA02000402A (es) | 2002-07-30 |
| CZ2002140A3 (cs) | 2002-05-15 |
| ZA200200303B (en) | 2003-03-26 |
| AU5930300A (en) | 2001-02-05 |
| KR20020012008A (ko) | 2002-02-09 |
| EP1198490A1 (en) | 2002-04-24 |
| RU2250911C2 (ru) | 2005-04-27 |
| EP1198490B1 (en) | 2006-02-15 |
| JP2003505401A (ja) | 2003-02-12 |
| KR20070086708A (ko) | 2007-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0012443A (pt) | Lipolìmero neutro e composições de lipossoma contendo o mesmo | |
| ATE383169T1 (de) | Komponente und zusammensetzungen zur verabreichung von wirkstoffen | |
| FI971776A (fi) | Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi | |
| TR199800436A2 (xx) | Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�. | |
| TR199902606T2 (xx) | Farnesil transferaz� engelleyici kinazolinonlar. | |
| TR200102603T2 (tr) | Antitümör aktiviteye sahip olan kamptotesin türevleri | |
| ATE178067T1 (de) | Camptothecinderivate | |
| BG103793A (en) | COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS | |
| RU2002100651A (ru) | Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы | |
| TR200002853T2 (tr) | Antitümör etkili indolil-3-glioksilik asit türevleri | |
| HK1036970A1 (en) | Compounds and compositions for delivering active agents. | |
| TNSN98075A1 (fr) | Analogues peptidiques de la lh-rh, leur utilisation et les compositions pharmaceutiques les contenant. | |
| TR199902383T2 (xx) | Yeni pirimidin t�revleri ve bunlar�n haz�rlanmas� i�in proses. | |
| TR199802289A2 (xx) | Fosfonasit-ikame etmi� benzazepinon-n-asetikasit t�revleri. | |
| EP2082740A3 (en) | Use of imidazole derivatives as MDR modulators | |
| EE05719B1 (et) | L-karnitiini või alkanoüül-L-karnitiinide estrite kasutamine katioonsete lipiididena farmakoloogiliselt aktiivsete komponentide intratsellulaarseks kohaletoimetamiseks | |
| TR200101663T2 (tr) | Pro-kollajen c-proteinaz inhibitörleri | |
| TR200103624T2 (tr) | Amof bileşikler ve bunların farmasötik bileşimleri. | |
| BR0001201A (pt) | Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica | |
| EA200101241A1 (ru) | Производные индола | |
| TR200101493T2 (tr) | Eletriptan hidrobromid monohidrat | |
| DE69928646D1 (de) | Derivate des streptogramins, ihre herstellung und sie enthaltende zubereitungen | |
| BR9811954A (pt) | ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias | |
| TR200001721T2 (tr) | Metalloprotein inhibitörleri olarak azulen hidroksamik asit türevleri. | |
| BR9914739A (pt) | éster de ácido fosfórico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: A61K 47/34, A61K 9/127, A61K 47/42, C08G 65/239 Ipc: A61K 47/34 (2009.01), A61K 9/127 (2009.01), A61K 4 |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ART. 8O, 10( VIII ), 13, 24 E 25 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |